Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice

被引:10
|
作者
Xia, Jun [1 ]
Wang, Lingling [1 ]
Zhou, Xin [1 ]
Wang, Jing [1 ]
Wang, Huan [1 ]
Guo, Hongfeng [1 ]
机构
[1] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Hematol, 299 Qingyang Rd, Wuxi 214023, Peoples R China
关键词
Elderly; multiple myeloma; early mortality; bortezomib; International Staging System; lactate dehydrogenase; CLINICAL-FEATURES; STAGING SYSTEM; THERAPY; AGE; MANAGEMENT; SURVIVAL;
D O I
10.1177/0300060518757640
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. Methods Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. Results EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM. The most common cause of death was infection (10/16, 62.5%). In the multivariate analysis, only an age of 75 years, International Staging System (ISS) stage III disease, and high lactate dehydrogenase concentration were significantly and independently associated with EM. Conclusion Our results suggest that infection is the leading cause of EM in elderly patients with MM. An age of 75 years, ISS stage III disease, and a high lactate dehydrogenase concentration are significant predictors of EM. We should further target this higher-risk patient population to define personalized therapy with which to improve outcomes.
引用
收藏
页码:2230 / 2237
页数:8
相关论文
共 50 条
  • [31] Real-world treatment practice in patients with advanced melanoma
    Cybulska-Stopa, Bozena
    Piejko, Karolina
    Pacholczak, Renata
    Domagata-Haduch, Malgorzata
    Drosik-Kwasniewska, Anna
    Rolski, Janusz
    Wiktor-Mucha, Patrycja
    Zemetka, Tomasz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2020, 24 (02): : 118 - 124
  • [32] Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma
    Juraj Sokol
    Tomas Guman
    Juraj Chudej
    Monika Hlebaskova
    Natalia Stecova
    Lubica Valekova
    Monika Kucerikova
    Jan Stasko
    Annals of Hematology, 2022, 101 : 81 - 89
  • [33] Real-World Clinical Outcomes in Patients With Multiple Myeloma Administered With Elotuzumab-Based Treatment
    Kikuchi, Taku
    Tsukada, Nobuhiro
    Oda, Yuki
    Nomura-Yogo, Moe
    Takei, Tomomi
    Sato, Kota
    Ogura, Mizuki
    Abe, Yu
    Suzuki, Kenshi
    Ishida, Tadao
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [34] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [35] Multiple myeloma (MM): Loss of patients per treatment line in a single real-world center
    Steinmetz, T.
    Bergmann, M.
    Heinz, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 115 - 116
  • [36] Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma
    Bruno, Amanda S.
    Willson, Jenny L.
    Opalinska, Joanna M.
    Nelson, Jeanenne J.
    Lunacsek, Orsolya E.
    Stafkey-Mailey, Dana R.
    Willey, Joanne P.
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 1017 - 1025
  • [37] Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment
    Taku Kikuchi
    Nobuhiro Tsukada
    Moe Nomura
    Yuki Kasuya
    Yuki Oda
    Kota Sato
    Tomomi Takei
    Mizuki Ogura
    Yu Abe
    Kenshi Suzuki
    Tadao Ishida
    Annals of Hematology, 2023, 102 : 1477 - 1483
  • [38] Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma.
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeanenne Joy
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment
    Kikuchi, Taku
    Tsukada, Nobuhiro
    Nomura, Moe
    Kasuya, Yuki
    Oda, Yuki
    Sato, Kota
    Takei, Tomomi
    Ogura, Mizuki
    Abe, Yu
    Suzuki, Kenshi
    Ishida, Tadao
    ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1477 - 1483
  • [40] Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Zhang, Shijia
    Richter, Joshua R.
    Kuo, Yen-Hong
    Schmidt, Linda
    McBride, Laura
    Anand, Palka
    Ivanovski, Kristin
    Pierre, Amy
    Kumka, Susan
    Cuccurullo, Carmela
    Siegel, David S.
    BLOOD, 2016, 128 (22)